← All trials
NCT05990738
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 11, 2024
- Primary completion
- Oct 27, 2025
- Completion date
- Dec 31, 2025
- First posted
- Aug 14, 2023
- Last posted
- Dec 28, 2023
- Enrollment
- 44
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Boehringer IngelheimLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.